{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:16:52Z","timestamp":1793038612833,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcf.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T09:21:26Z","timestamp":1635931286000},"page":"339-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Suyeon","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Safirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-6445","authenticated-orcid":false,"given":"Brian","family":"Bourque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-3697","authenticated-orcid":false,"given":"Martine H.","family":"Antell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Diloreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2021.10.002_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-4-5","article-title":"Review of the use of Topiramate for treatment of psychiatric disorders","volume":"4","author":"Arnone","year":"2005","journal-title":"Ann Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.jcf.2021.10.002_bib0002","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2105\/AJPH.2019.305007","article-title":"US emergency department visits for acute harms from prescription opioid use, 2016\u20132017","volume":"109","author":"Lovegrove","year":"2019","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.jcf.2021.10.002_bib0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/108482239000200312","article-title":"Drug-induced mental status changes","volume":"2","author":"McPherson","year":"1990","journal-title":"J Home Health Care Pract"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.9740\/mhc.2016.07.201","article-title":"Drug-induced cognitive impairment: Effect of cardiovascular agents","volume":"6","author":"Marvanova","year":"2016","journal-title":"Ment Health Clin"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0005","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0002-9343(91)80097-6","article-title":"Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole","volume":"90","author":"McCue","year":"1991","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.jcf.2021.10.002_bib0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0019-5545.39762","article-title":"Levofloxacin-induced acute psychosis","volume":"50","author":"Moorthy","year":"2008","journal-title":"Indian J Psychiatry"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1139\/O10-016","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in paracervical ganglia","volume":"88","author":"Su","year":"2010","journal-title":"Biochem Cell Biol"},{"issue":"11","key":"10.1016\/j.jcf.2021.10.002_bib0008","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1369\/0022155414546190","article-title":"Cystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: comparative immunohistochemical study between patients with normal and mutated CFTR","volume":"62","author":"Marcorelles","year":"2014","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"10.1016\/j.jcf.2021.10.002_bib0009","doi-asserted-by":"crossref","first-page":"00127","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/da.22227","article-title":"Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections","volume":"31","author":"Duman","year":"2014","journal-title":"Depress Anxiety"},{"issue":"5 Suppl 1","key":"10.1016\/j.jcf.2021.10.002_bib0011","first-page":"1","article-title":"Anxiety and depression in cystic fibrosis","volume":"106","author":"Baiardini","year":"2015","journal-title":"Minerva Med"},{"issue":"6","key":"10.1016\/j.jcf.2021.10.002_bib0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jpeds.2015.07.048","article-title":"Identifying differences in risk factors for depression and anxiety in pediatric chronic disease: a matched cross-sectional study of youth with lupus\/mixed connective tissue disease and their peers with diabetes","volume":"167","author":"Knight","year":"2015","journal-title":"J Pediatr."},{"issue":"3","key":"10.1016\/j.jcf.2021.10.002_bib0013","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.jcf.2021.10.002_bib0016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.10.002_bib0017","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.10.002_bib0018","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","author":"Safirstein","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.10.002_bib0019","article-title":"Azithromycin and tezacaftor\/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis","author":"Song","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2021.10.002_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(21)00059-4","article-title":"Long COVID: understanding the neurological effects","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jcf.2021.10.002_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321021044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321021044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:03Z","timestamp":1761601623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321021044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1569199321021044"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.10.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}